Shailesh K. Choudhary

TL;DR: It is demonstrated that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.

TL;DR: It is demonstrated that a combination of tenofovir, emtricitabine, and raltegravir effectively suppresses peripheral and systemic HIV replication in humanized BLT mice.

TL;DR: The in vivo efficacy of a targeted cytotoxic therapy to kill infected cells that persist despite long-term ART is determined and it is found that compared to ART alone, this agent profoundly depleted productively infected cells systemically.

TL;DR: The highest levels of intestinal human T cells throughout the small and large intestines were observed in N/S-BLT mice, which have an intact common γ-chain molecule, indicating that N/s-BLt mice are well suited for the analysis of human intestinal lymphocyte trafficking and human-specific diseases affecting the intestines.

TL;DR: The molecular targets that might be exploited to induce HIV-1 expression, remove epigenetic restrictions, or enhance effective transcription are identified and the potential pharmacologic approaches toward targeting viral persistence in different cellular and anatomical reservoirs are discussed.